Cas no 132866-11-6 (Lercanidipine hydrochloride)

Lercanidipine hydrochloride is a dihydropyridine calcium channel blocker used primarily as an antihypertensive agent. It exhibits high lipophilicity, enabling selective and prolonged interaction with L-type calcium channels in vascular smooth muscle, resulting in sustained vasodilation. The compound's slow onset of action minimizes reflex tachycardia, a common side effect of other calcium antagonists. Its pharmacokinetic profile includes extensive tissue distribution and hepatic metabolism, with negligible renal excretion, making it suitable for patients with renal impairment. Lercanidipine hydrochloride demonstrates dose-dependent efficacy in reducing blood pressure while maintaining a favorable tolerability profile, with a low incidence of peripheral edema compared to other dihydropyridines. It is typically administered once daily due to its extended duration of action.
Lercanidipine hydrochloride structure
Lercanidipine hydrochloride structure
Product Name:Lercanidipine hydrochloride
CAS No:132866-11-6
MF:C36H42ClN3O6
MW:648.188189029694
MDL:MFCD07773089
CID:64223
PubChem ID:24724527
Update Time:2025-10-31

Lercanidipine hydrochloride Chemical and Physical Properties

Names and Identifiers

    • 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-
    • pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
    • LERCANIDIPINE HCL
    • LERCANIDIPINE HYDROCHLORIDE
    • 1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylicAcid2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimeth
    • 1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylic Acid 2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimethylethyl Methyl Ester Hydrochloride
    • LERCANIDIPINEHYDROCHLORIDE(FORR&DONLY)
    • Lercanidipine hydrochloride hemihydrate
    • Lercanidipine (hydrochloride)
    • 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride
    • 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
    • R 75
    • CLAP
    • mE10
    • BCL10
    • c-E10
    • CIPER
    • CarMen
    • Lercan
    • LerzaM
    • Zandip
    • Cardiovasc
    • Corifeo
    • Zanicor
    • Lerkamen
    • Vasodip
    • Renovia
    • Lercaton
    • Lercapin
    • Lercadip
    • Zanidip (hydrochloride)
    • Masnidipine (hydrochloride)
    • 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2
    • Rec-15/2375
    • AS-13358
    • 2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimethylethyl methyl (4RS)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride
    • AC-1420
    • LERCANIDIPINE HYDROCHLORIDE [WHO-DD]
    • NCGC00260829-01
    • DTXSID3046665
    • J-521641
    • Lercanidipine hydrochloride (JAN/USAN)
    • NCGC00167492-01
    • FT-0670749
    • TJN-324
    • OA8TFX68PE
    • SCHEMBL217099
    • 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)
    • LERCANIDIPINE HYDROCHLORIDE [MART.]
    • NCGC00167492-03
    • Masnidipine hydrochloride
    • 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
    • HY-B0612A
    • CHEMBL2106419
    • L0282
    • Cardiovasc (TN)
    • Lercanidipine hydrochloride- Bio-X
    • 132866-11-6
    • Tox21_112493_1
    • 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
    • 3,5-Pyridinedicarboxylic acid, 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester, monohydrochloride
    • Zanidip hydrochloride
    • FT-0627794
    • Q27285537
    • BCP11375
    • LCP-Lerc
    • UNII-OA8TFX68PE
    • 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester, hydrochloride (1:1)
    • AKOS015846519
    • LERCANIDIPINEHCL
    • 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester, monohydrochloride
    • MFCD07773089
    • Lerdip
    • Lercanidipine hydrochloride [USAN]
    • LERCANIDIPINE HYDROCHLORIDE [MI]
    • CHEBI:31771
    • s4597
    • Tox21_112493
    • CCG-270327
    • 3,3-diphenylpropyl-[2-[5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl]oxy-2-methylpropyl]-methylazanium;chloride
    • 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] ester O3-methyl ester hydrochloride
    • J-006235
    • LP00144
    • WMFYOYKPJLRMJI-UHFFFAOYSA-N
    • Lercanidipine hydrochloride, >=98% (HPLC)
    • 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4RS)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride
    • A806509
    • BL164618
    • Zanidip
    • CCG-221448
    • Tox21_500144
    • 3-(1-((3,3-Diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride(1:x)
    • FT-0631144
    • LERCANIDIPINE HYDROCHLORIDE [JAN]
    • CAS-132866-11-6
    • O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
    • 100427-27-8
    • FT-0670750
    • DTXCID1026665
    • D01849
    • J-006236
    • Zanedip
    • DB-042142
    • Lercanidipine hydrochloride
    • MDL： MFCD07773089
    • Inchi： 1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H
    • InChI Key： WMFYOYKPJLRMJI-UHFFFAOYSA-N
    • SMILES： Cl.O(C(C1=C(C)NC(C)=C(C(=O)OC)C1C1C=CC=C(C=1)[N+](=O)[O-])=O)C(C)(C)CN(C)CCC(C1C=CC=CC=1)C1C=CC=CC=1

Computed Properties

  • Exact Mass: 647.27600
  • Monoisotopic Mass: 647.276
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 8
  • Heavy Atom Count: 46
  • Rotatable Bond Count: 13
  • Complexity: 1090
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 114

Experimental Properties

  • Color/Form: Gray white yellow powder
  • Melting Point: 119-123°C
  • Boiling Point: 712.5°C at 760 mmHg
  • Flash Point: 384.7oC
  • PSA: 113.69000
  • LogP: 8.13240
  • Merck: 5446
  • Sensitiveness: Photosensitive, moisture sensitive
  • Vapor Pressure: No data available

Lercanidipine hydrochloride Security Information

  • Symbol: GHS06
  • Prompt：warning
  • Signal Word：Danger
  • Hazard Statement： H301
  • Warning Statement： P301+P310
  • Hazardous Material transportation number：UN 2811
  • WGK Germany：3
  • Hazard Category Code： 25
  • Safety Instruction： S36/37-S45
  • Hazardous Material Identification： T
  • Risk Phrases：R25
  • Toxicity：LD50 in mice (mg/kg): 83 i.p.; 657 orally (Nardi)
  • HazardClass：6.1
  • PackingGroup：III
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Lercanidipine hydrochloride Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.
CB01247-0.1g
Lercanidipine hydrochloride
 132866-11-6 97%
0.1g
 159.00 2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.
CB01247-0.25g
Lercanidipine hydrochloride
 132866-11-6 97%
0.25g
 235.00 2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.
CB01247-1g
Lercanidipine hydrochloride
 132866-11-6 97%
1g
 503.00 2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.
CB01247-5g
Lercanidipine hydrochloride
 132866-11-6 97%
5g
 1726.00 2021-06-01
S e l l e c k ZHONG GUO
S4597-10mg
Lercanidipine hydrochloride
 132866-11-6 99.98%
10mg
 ￥573.35 2023-09-15
S e l l e c k ZHONG GUO
S4597-50mg
Lercanidipine hydrochloride
 132866-11-6 99.98%
50mg
 ￥2022.94 2023-09-15
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R022181-1g
Lercanidipine hydrochloride
 132866-11-6 98%
1g
 ￥280 2023-09-10
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R022181-10mg
Lercanidipine hydrochloride
 132866-11-6 98%
10mg
 ￥32 2023-09-10
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R022181-50mg
Lercanidipine hydrochloride
 132866-11-6 98%
50mg
 ￥55 2023-09-10
ChemScence
CS-2831-10mg
Lercanidipine (hydrochloride)
 132866-11-6 99.94%
10mg
 $55.0 2022-04-27

Lercanidipine hydrochloride Related Literature

Related Categories

Additional information on Lercanidipine hydrochloride

Lercanidipine Hydrochloride (CAS No. 132866-11-6): A Comprehensive Overview of Its Pharmacology and Clinical Applications

Lercanidipine hydrochloride (CAS No. 132866-11-6) is a highly selective calcium channel blocker (CCB) belonging to the dihydropyridine class. It is widely prescribed for the management of hypertension (high blood pressure) due to its potent vasodilatory effects and favorable safety profile. The compound's unique pharmacokinetic properties, including lipophilicity and tissue selectivity, make it a preferred choice among clinicians for long-term cardiovascular therapy.

One of the most searched questions about Lercanidipine HCl is its mechanism of action. Unlike older CCBs, Lercanidipine exhibits slow-onset, long-lasting effects by selectively inhibiting L-type calcium channels in vascular smooth muscle. This results in reduced peripheral vascular resistance without significantly affecting cardiac output—a key advantage for patients with comorbid conditions like stable angina or diabetic hypertension. Recent studies highlight its role in endothelial function improvement, a hot topic in cardiovascular research.

The pharmacokinetics of Lercanidipine hydrochloride (CAS 132866-11-6) also attracts significant attention. With high protein binding (>98%) and extensive first-pass metabolism, it achieves steady-state plasma concentrations within 48 hours. Its food-dependent absorption (enhanced by fatty meals) is frequently discussed in patient forums, emphasizing the need for proper administration timing. Notably, its terminal half-life of 8-10 hours allows for convenient once-daily dosing, improving medication adherence—a major concern in chronic disease management.

Emerging trends show growing interest in Lercanidipine HCl combination therapies. Clinicians often pair it with ACE inhibitors or angiotensin receptor blockers (ARBs) for synergistic effects, particularly in patients with renal impairment. A 2023 meta-analysis underscored its nephroprotective potential in hypertensive patients with mild-to-moderate CKD, aligning with current focus on organ-protective antihypertensives.

Safety profiles remain a top search priority. Lercanidipine hydrochloride demonstrates fewer incidences of ankle edema (a common CCB side effect) due to its vascular selectivity. However, discussions on drug interactions with CYP3A4 inhibitors (e.g., grapefruit juice) persist in medical communities. Ongoing research explores its potential in pulmonary hypertension and cerebrovascular protection, reflecting evolving therapeutic applications.

From a pharmaceutical chemistry perspective, the 132866-11-6 compound exhibits crystalline structure stability under standard storage conditions. Its synthesis involves asymmetric hydrogenation—a process frequently queried by chemistry enthusiasts. The drug's partition coefficient (log P 6.5) explains its high membrane permeability, a feature leveraged in novel transdermal delivery systems under investigation.

In conclusion, Lercanidipine hydrochloride (CAS 132866-11-6) represents a refined therapeutic option within the CCB class. Its balanced efficacy, organ protection benefits, and patient-centric pharmacokinetics address contemporary demands in hypertension management. As precision medicine advances, its role in personalized cardiovascular care continues to expand, supported by robust clinical evidence and real-world outcomes data.

132866-11-6 (Lercanidipine hydrochloride) Related Products

Recommended suppliers
Enjia Trading Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Enjia Trading Co., Ltd
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.
上海嶸奧生物技術(shù)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
上海嶸奧生物技術(shù)有限公司
SHOCHEM(SHANGHAI) CO.,lTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SHOCHEM(SHANGHAI) CO.,lTD
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd